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Abstract Introduction: Cognition is under strong genetic control, yet the specific genes are unknown.
Methods: One hundred and fifty-three cognitive healthy European subjects from the Reference Abil-
ities Study (RANN) were genotyped for 1,160 variants within 446 neuropsychiatric genes. Adjusted
linear regression models evaluated the association between the genetic variants and four reference
abilities (Vocabulary, Episodic Memory, Perceptual Speed, and Reasoning).
Results: One hundred and fifty-nine variants nominally were found significant in the RANN cohort
and re-evaluated in an independent cohort of 868 cognitive healthy subjects from the Religious
Orders Study and Rush Memory Aging Project. Meta-analysis yielded a Bonferroni adjusted statis-
tically significant association between perceptual speed and a variant located in the promoter of the
dopamine receptor D4 gene, rs3756450 (b 5 0.23, standard error 5 0.05, Pmeta 5 2.3! 10
25).
Discussion: Our data suggest that genetic variation in a dopamine pathway gene influences percep-
tual speed performance in cognitively healthy individuals.
 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
Keywords: Cognitive performance; Cognitive healthy subjects; Candidate genes SNP association; Meta-analysis; Dopamine
pathway
1. Introduction
A significant proportion of the differences observed in
cognitive performance is attributable to genetic variability.
Cross-sectional and longitudinal twin studies have consis-
tently shown strong genetic influences on cognitive perfor-
mance, in both normal variation and in the extremes of the
normal distribution [1,2]. Results from a meta-analysis of
23 independent twin studies also showed that heritability
estimates vary across the different specific domains [3].
Several studies have reported genetic associations with
a priori biological relevant genes for cognition; however,
results have not been consistently replicated [4–13].
Genetic-agnostic approaches through genome-wide associ-
ation analysis (GWAS) have also been reported for
different cognitive tasks [14–21]. GWAS studies have
examined cognition in the context of pathologic
cognitive variation, that is, Alzheimer’s disease (AD)
[22–28], and also in normal variation in healthy adults.
Some of the loci reported in recent GWAS of cognitive
function in middle and older nondemented subjects have
been previously associated with AD [15–17], suggesting
a possible genetic overlap between normal and
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pathologic cognitive variation in older age. However, some
other studies have reported that many loci previously
implicated in Late Onset Alzheimer’s Disease (LOAD)
were not associated with any cognitive domain [28,29]
or AD pathology [30]. To better understand the natural dis-
ease resistance to brain neurodegeneration, increasing
number of genetic studies are focusing on cognitive
healthy individuals. The identification of genetic variants
influencing cognitive function in nondemented cohorts
can elucidate molecular mechanisms for preventing or de-
laying cognitive decline.
Among the main limitations of GWAS are the small ge-
netic effects of the identified variants and the very stringent
multiple testing correction needed to achieve genome-wide
significance (P  6! 1028) [31]. Alternative gene identifi-
cation approaches include hypothesis-driven gene-based
analysis, that is, candidate gene(s), which rely on already
available experimental data that support the involvement
of the genes being tested. The use of smaller focused
single-nucleotide polymorphism (SNP) arrays represents a
practical approach where SNPs cover a limited number of
biological candidate genes. Such focused SNP arrays offer
the advantages of lower cost and lower false discovery
rate, especially in situations where a data set may have inad-
equate power for GWAS because of either size or other
reasons [32].
The candidate gene approach has been questioned
because of nonreplication of results and limits on its ability
to include all possible causative polymorphisms [33]. How-
ever, rigorous epidemiologic principles, as previously
described [33], may considerably improve its success. In
addition, efforts from different human genome sequencing
initiatives, such as 1000 genome sequencing project, provide
extensive high coverage data information (genomic, tran-
scriptomic, epigenomic, and proteomics) that will helpfully
contribute to overcoming the shortcomings of the candidate
gene approach [34].
Our candidate gene approach focused on genes
previously investigated [32] based on their roles as func-
tional domains important in psychiatric neurogenetics.
Neurobiological studies of addiction, mood disorders,
and psychoses have established the importance of mecha-
nisms such as reward, stress resiliency, and executive
cognitive control [35]. Among the implicated molecular
networks and genes integral to those processes are
signaling networks, stress/endocrine genes, and key
neurotransmitter systems including dopamine (DA), sero-
tonin, glutamate, g-amino butyric acid (GABA), and
acetylcholine.
We investigated whether SNPs tagging genes that are key
players in different neurologic molecular networks (pharma-
cogenomics, pharmacodynamics, and behavioral) may influ-
ence individual performance on four previously reported
reference abilities (RAs): episodic memory, fluid reasoning,
perceptual speed, and vocabulary.
2. Methods
2.1. Study samples
Subjects were recruited from two different cohorts. Three
hundred twenty-nine participants were recruited from the
community for the Reference Ability Neural Network
(RANN) study (referred to as RANN sample), of which
only those with Caucasian ancestry (n 5 153) were consid-
ered for analysis purposes, and 868 Caucasian participants
from the Religious Orders Study and Rush Memory and
Aging Project (ROSMAP sample).
2.2. RANN sample
2.2.1. Study participants
The RANN study includes healthy adults for whom
cognitive assessment and MRI imaging are available. Sub-
jects were free of medical or psychiatric conditions that
could affect cognition. Detailed description of the cohorts
can be found elsewhere [36].
2.2.2. Computation of cognitive phenotypes from
neuropsychology data
A battery of 12 neuropsychological tests was selected to
assess cognitive functioning in four cognitive domains:
episodicmemory, reasoning ability, perceptual speed, and vo-
cabulary. Previous analyses demonstrated that the included
tasks described latent unique latent variables for the four
cognitive domains [37,38]. There were some missing data
for the neuropsychological measures, but we decided to be
as inclusive as possible. We therefore calculated average
z-scores within each domain over all the three measures that
were available; a missing value for the domain z-score was
assigned only when all three measures were missing. All
measures were adjusted such that a larger value indicated
better performance, that is, completion times were flipped
in sign. The measures that made up the domain z-scores all
showed high correlation, lending good support for internal
consistency, as can seen subsequently.
Three memory measures were based on subscores of the
Selective Reminding Task (SRT) [39]. Participants in this
task were initially asked to read a list of 12 words and
then asked to recall as many as they could. For the following
five trials they were reminded of the words that they did not
report and were asked to again recall all the words in the list.
Words are considered to enter long-term storage from the
point when they are recalled twice in a row without re-
minders. The long-term storage subscore (SRT_LTS) is the
sum over all words of the number of trials when each
word was in long-term storage. Continuous long-term
retrieval (SRT_CLRT) is the sum over all words of the num-
ber of trials for which the word was continuously recalled.
The third memory measure was the number of words re-
called on the last trial (SRTLast).
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Reasoning ability was assessed with scores on three
different tests. One test was the Wechsler Adult Intelligence
Scale (WAIS) III Block Design test [40], in which partici-
pants were asked to reproduce a series of increasingly com-
plex geometrical shapes using four or nine identical blocks
with red, white, or split red and white sides. A second test
was the WAIS III Letter-Number Sequencing test [40] in
which participants were asked to recall progressively longer
lists of intermixed letters and numbers in alphabetical and
then numerical order. The third reasoning test was theMatrix
Reasoning subtest from WAIS III [41] in which participants
were asked to select which pattern in a set of eight possible
patterns best completes a missing cell in a matrix. The two
pairwise correlations between all three measures yielded a
minimum value of R 5 0.28, P 5 1025.
Three measures were selected to assess perceptual speed.
One was the score on the Digit Symbol subtest from the
WAIS III [40]. Participants in this test were instructed to
write the symbol corresponding to specific numbers as
quickly as possible based on a key specifying the appropriate
symbol for each digit. The score is the number of correctly
produced symbols in 90 seconds. A second measure was
the score on Part A of the Trail Making Test [42], in which
participants were instructed to connect circles numbered
from 1 to 24 as rapidly as possible and performance is as-
sessed as the time to connect all 24 circles. The third speed
measure was the number of colored ink patches named in
45 seconds in the Stroop Color Naming test.
Vocabulary was assessed with scores on the vocabulary
subtest from the WAIS III [41], the Wechsler Test of Adult
Reading [40], and the error score of the American National
Adult Reading Test [43]. The vocabulary subtest asks partic-
ipants to provide definitions for a series of increasingly
advanced words, and the Wechsler Test of Adult Reading
and National Adult Reading Test both involve participants
correctly pronouncing irregularly spelled English words.
2.2.3. SNP genotyping array
A total of 329 study participants were genotyped for 1160
SNP arrays. Most variants (1129 SNPs from 415 candidate
genes) were selected from a previously published array
aimed to interrogate candidate genes in alcoholism, other ad-
dictions, and disorders of mood and anxiety [32].
Most genes represent the domains of vulnerability to drug
use and pharmacodynamics response (DA, serotonin, gluta-
mine, GABA, and opioid neurotransmitter genes), signaling
genes, and genes modulating stress resiliency and behavioral
dyscontrol domains. Candidate genes involved in pharmacoki-
netic domains (acohol dehydrogenase [ADH] gene cluster, and
aldehydedehydrogenases [ALDH] genes) are also represented.
There is a high degree of overlap between functional gene cat-
egories because of pleiotropic actions of molecules on
behavior. The array was subsequently complemented with
the addition of variants in candidate genes (24 SNPs) that
have been previously associated with increased risk of
LOAD [44] and variants in candidate genes (seven SNPs)
reported as associated with episodic memory performance
[11–13,19].
2.2.4. Population stratification analysis
Because of the heterogeneous ethnic background of the
RANN participants, we evaluated whether distribution of
SNP frequencies differ among the different ethnic groups.
Population stratification analysis were conducted using
STRUCTURE software [45], which uses a systematic
Bayesian clustering approach applyingMarkovChainMonte
Carlo estimation to place subjects into groups whose mem-
bers share similar patterns of genetic variation. To maximize
genotype information in the estimation of the different pop-
ulation clusters, RANN genetic data were complemented
with publicly available SNP data from HapMap European,
African, and Native populations (http://www.sanger.ac.uk/
resources/downloads/human/hapmap3.html). SNPs in the
RANN cohort were pruned based on the linkage disequilib-
rium pattern, and only SNPs in high linkage disequilibrium
(r2  0.8) were retained.
2.2.5. Single-marker SNP tests of association
Quality control of the SNP genotype data excluded SNPs
with nonbiallelic distribution, minimum allele frequencies
lower than 10% and with genotype frequencies significantly
deviated from Hardy-Weinberg equilibrium (P, .001). SNP
association with the four different RAs was assessed with
linear regression assuming an additive model using PLINK
[46]. All analyses were adjusted for sex, age, and education.
Adjustment for multiple testing using Bonferroni correction
(787 SNPs, four RAs tested) establishes the threshold for
experimentwise significant as P  1.6 ! 1025. However,
because of the limited sample size of the RANN cohort,
SNPs achieving nominal significance (P  .05) were
selected for replication purposes.
2.3. ROSMAP sample
2.3.1. Study participants
The ROS participants are older Catholic nuns, priests, and
brothers from groups across the United States.MAP includes
older individuals from the metropolitan Chicago area. At the
time of enrollment, participants were at least 50-year-old
nondemented subjects. Detailed description of the cohorts
can be found elsewhere [47,48]. The present analysis was
restricted to cognitively healthy Caucasian participants.
2.3.2. Cognitive phenotypes
Nineteen tasks, from a battery of 21 cognitive perfor-
mance tests, were chosen to assess four domains of cognitive
function: episodic memory, perceptual speed, perceptual
orientation, and vocabulary. The individual cognitive tests
included in each of the cognitive domains are briefly listed
subsequently. Detailed description of the individual can be
found elsewhere [49]. Composite measures of the specific
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cognitive domains were created by converting each test
within each domain into a z-score and averaging the z-scores
as previously described [50].
Episodic memory domain included seven measures of
memory: immediate and delayed recall of story A from
Logical Memory and of the East Boston Story and Word
List Memory, Word List Recall, and Word List Recognition.
The four measures selected to assess perceptual speed
included Symbol Digit Modalities Test, Number Compari-
son, and two indices from a modified version of the Stroop
Neuropsychological Screening Test.
Perceptual orientation was assessed with scores on two
different tests, 15-item version of Judgment of Line Orienta-
tion and a 16-item version of Standard ProgressiveMatrices.
Scores on three tests were included to assess vocabulary:
a 15-item version of the Boston Naming Test, Verbal
Fluency, and a 15-item reading test.
2.3.3. Imputation of the genome-wide genotype data
SNP genotyping was done on the Affymetrix Genechip
6.0 or Illumina OmniQuad Express platform as previously
described [51]. Genotype imputation was performed with
BEAGLE [52] (version 3.3.2) and generated dosage data
on.35 million SNPs for each individual using the 1000 Ge-
nomes Project (2011 Phase 1b data freeze) as a reference.
Analyses were limited to SNPs with minor allele frequencies
0.01 and imputation quality scores .0.3. For the current
analysis, two different and independent imputed genotype
batches were used (ROSMAP1 and ROSMAP2).
2.3.4. Single-marker SNP tests of association
Similarly to the RANN cohort analyses, SNP association
with the four different cognitive phenotypes was assessed
with linear regression assuming an additive model using
PLINK [46]. All analyses were adjusted for sex, age, and
education.
2.3.5. Meta-analysis of RANN and ROSMAP cohorts
The results from the individual data sets were then
meta-analyzed using METAL [53] by weighting the effect
size estimates (b-coefficients), by their estimated standard
errors. The meta-analysis was also conducted in conjunc-
tion with Cochran’s Q-test for heterogeneity [54] to inves-
tigate whether observed effect sizes were homogeneous
across cohorts. Adjustment for multiple testing was carried
out using Bonferroni correction, SNPs achieving
P  3.1 ! 1024 (159 SNPs were tested in the meta-
analysis) were declared as statistically significant associ-
ated with the corresponding RA.
3. Results
Population stratification analyses clustered the total of
329 RANN participants into three ethnic subgroups:
(1) 153 subjects of Caucasian ancestry, (2) 85 subjects
with African-American ancestry, and (3) the remainder 91
subjects with mixed ethnicity. To minimize the risk of
false-positive associations, analyses were limited to the
Caucasian ancestry RANN participants.
The characteristics of the individual study cohorts are
shown in Table 1. Participants from ROSMAP were older
(856 7 vs. 546 17) and had a higher proportion of women
(70% vs. 50%) when compared with RANN participants. We
did not find significant differences in the average years of ed-
ucation between RANN and ROSMAP’s participants.
After quality control analyses in the RANN cohort, 787
SNPs were considered for association analyses (SNP charac-
teristics are shown in Supplementary Table 1). Evaluation of
the genetic association between SNPs and each of the RAs
yielded 159 SNPs that achieved nominal significant associ-
ations (P  .05) across the four RAs (28 SNPs nominally
associated with reasoning, 45 SNPs nominally associated
with episodic memory, 38 SNPs nominally associated with
speed, and 48 SNPs nominally associated with vocabulary).
The strongest SNP association was observed between vocab-
ulary and an intronic variant in the corticotropin-releasing
hormone receptor 1 gene (CRHR1 rs110402 b5 0.31, stan-
dard error 5 0.07, P 5 6.1! 1025), a gene that encodes a
receptor that binds neuropeptides of the corticotropin
hormone family, major regulators of the hypothalamic-
pituitary-adrenal pathway. Although the association
achieved experiment-wise statistical significance after Bon-
ferroni correction (P 1.6! 1025), the SNP was not found
to be significantly associated in the ROSMAP replication co-
horts (data not shown).
The subset of 159SNPs nominally associated variants in the
RANN cohort was tested for association in the ROSMAP co-
horts. SNP association results from RANN and ROSMAP co-
horts were then meta-analyzed. SNPs that achieved P, .05 in
the meta-analysis are shown in Table 2. Meta-analysis results
identified variant rs3758653 located in the promoter region
of the dopamine receptor D4 (DRD4) gene strongly associated
with perceptual speed, reachingstatistical significance after ad-
justing for multiple testing (Pmeta 5 2.3! 10
25). Compared
with carriers of the C allele at SNP rs3758653, carriers of
one or two copies of the T allele demonstrated better perfor-
mance on processing speed, that is, in the RANN cohort,
average speed performance (and standard deviation) was
0.03 (0.84) for Tallele carriers versus20.16 (0.74) for C allele
carriers. The heterogeneity test (Supplementary Table 1)
demonstrated that SNP effect was homogenous across the
Table 1
Characteristics of the study cohorts
Variable RANN ROSMAP
Number of individuals 153 939
% Female 50 70
Age, average 6 SD 54 6 17 85 6 7
Education, average 6 SD 17 6 2 17 6 4
Abbreviations: RANN, Reference Ability Neural Network Study,
Columbia University; ROSMAP, Religious Order and Rush Aging Project
cohorts; SD, standard deviations.
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different cohorts (P 5 .450), and in fact, the direction of the
SNP effect was consistent across the three cohorts.
Although not reaching statistical significance after multi-
ple testing correction (P  3.1! 1024), we observed in the
meta-analysis associations that reached nominal signifi-
cance and had a consistent direction of the genetic effect
across the three cohorts. For reasoning, the strongest associ-
ation was observed for an intronic variant in the
erythropoietin-producing hepatoma receptor A1 (EPHA1)
gene (Pmeta5 .002), a gene that has been reported to increase
the risk of developing LOAD. An intronic variant in the
GABA type A receptor Alpha4 (GABRA4) gene, involved
in the GABAergic neurotransmission of the central nervous
system, appeared to be associated with better performance
on episodic memory (Pmeta5 .014). Finally, a coding variant
in the solute carrier family 18 member A1 (SLC18A1) gene,
a vesicular monoamine transporter, was nominally signifi-
cant associated with vocabulary (Pmeta 5 .001).
4. Discussion
Our meta-analysis of genetic associations between SNPs
within neuropsychiatric pathway genes and cognitive
domains identified a variant in the promoter region of the
DRD4 gene strongly associated with performance on speed
of processing (Pmeta 5 2.3 ! 10
25) in cognitively healthy
subjects.
Dopamine, a catecholamine neurotransmitter, influences
cognition and motor/limbic functions [55]. Dysfunction of
the dopaminergic system is involved in a variety of disorders,
including schizophrenia, Parkinson’s disease, and drug addic-
tion.
Substantial evidence from animal studies has shown
the key role of dopamine in regulating performance
across a variety of cognitive domains. For example, in
rodents and monkeys lesions of dopaminergic nerve
terminals at different sites lead to impartment in memory
and spatial attention functions [56]. Patients with
Huntington’s and Parkinson’s disease have demonstrated
deficits across multiple cognitive domains including
episodic memory, verbal fluency, perceptual speed, and
reasoning [57,58]. Pharmacologic studies have shown
administration of psychostimulant drugs or antagonists
of dopamine receptors are associated with enhancement/
impairment of performance in tasks such as processing
speed [59,60].
Table 2
Meta-analysis of RANN and ROSMAP cohorts
Reference abilities Gene SNP
RANN ROSMAP_b1 ROSMAP_b2 Meta-analysis
A1 b SE P A1 b SE P A1 b SE P b SE Pmeta Dir.
Episodic memory GABRA4 rs4695183 C 20.42 0.17 .014 T 0.07 0.05 .163 T 0.14 0.10 .172 0.11 0.04 .014 111
Episodic memory GRIN2B rs2192977 A 0.29 0.10 .004 T 20.07 0.03 .027 T 0.02 0.05 .696 0.06 0.02 .014 112
Episodic memory GRIN2B rs12829455 A 20.23 0.10 .029 G 0.03 0.03 .445 G 0.06 0.05 .210 20.05 0.02 .045 222
Reasoning SLC6A11 rs2581206 C 20.17 0.08 .032 A 0.07 0.08 .352 A 0.03 0.15 .833 0.11 0.05 .040 111
Reasoning SLC6A11 rs1881354 A 20.16 0.08 .045 G 0.09 0.08 .271 G 0.03 0.15 .861 20.11 0.05 .033 222
Reasoning CDKL3 rs326626 G 20.23 0.11 .043 C 0.10 0.13 .447 C 0.38 0.25 .136 0.20 0.08 .014 111
Reasoning NR3C1 rs6877893 G 20.18 0.07 .017 G 20.10 0.07 .155 G 0.03 0.15 .831 0.12 0.05 .009 112
Reasoning EPHA1 rs11767557 C 20.23 0.10 .024 T 0.15 0.09 .107 T 0.27 0.19 .165 0.20 0.06 .002 111
Reasoning ADRA1A rs2644627 C 20.19 0.08 .016 G 0.07 0.08 .361 G 0.02 0.15 .886 20.12 0.05 .028 222
Reasoning NTRK2 rs11795386 T 20.24 0.09 .013 C 0.11 0.10 .267 C 20.18 0.20 .376 20.15 0.06 .022 221
Reasoning CH25H rs11203006 G 0.23 0.12 .046 A 20.10 0.11 .398 A 20.09 0.19 .634 20.15 0.07 .046 222
Reasoning MAPT rs8079215 C 0.19 0.09 .045 T 20.11 0.08 .212 T 0.14 0.18 .454 20.12 0.06 .039 221
Reasoning GALR1 rs2717164 G 20.39 0.16 .020 T 0.18 0.30 .553 T 1.04 0.68 .126 0.37 0.14 .007 111
Speed GABRA4 rs1398176 T 20.33 0.10 .002 C 0.05 0.06 .433 C 20.01 0.12 .905 20.10 0.05 .029 221
Speed GABRB1 rs971353 C 20.19 0.09 .035 T 0.13 0.05 .008 T 0.03 0.10 .765 0.13 0.04 .002 111
Speed RP1L1 rs4841401 C 20.22 0.07 .004 G 0.02 0.05 .626 G 0.19 0.09 .034 20.10 0.04 .005 222
Speed DRD4 rs3758653 C 20.23 0.09 .010 T 0.15 0.09 .094 T 0.32 0.10 .002 0.23 0.05 2.3! 1025 111
Speed CHRNA5 rs7180002 T 0.17 0.07 .021 T 0.05 0.05 .262 T 0.19 0.08 .023 20.11 0.04 .002 222
Speed SLC6A2 rs36008 A 0.41 0.20 .044 T 20.18 0.15 .234 T 20.17 0.30 .565 0.25 0.11 .025 111
Speed GALR1 rs2717164 G 20.33 0.15 .033 T 0.16 0.17 .341 T 0.63 0.38 .100 0.29 0.11 .008 111
Speed GRIK1 rs457474 C 20.36 0.10 3.2! 1024 G 0.05 0.06 .354 G 0.16 0.11 .162 20.14 0.05 .003 222
Vocabulary CREB1 rs2551640 G 20.19 0.08 .013 G 20.05 0.05 .298 G 20.07 0.08 .396 0.09 0.04 .023 111
Vocabulary LPCAT1 rs3756450 G 20.28 0.12 .021 A 0.10 0.07 .128 A 0.02 0.11 .871 0.12 0.05 .028 111
Vocabulary EPHA1 rs11767557 C 20.20 0.10 .045 T 0.05 0.05 .314 T 0.31 0.10 .002 0.12 0.04 .004 111
Vocabulary SLC18A1 rs2270641 G 20.22 0.08 .004 G 20.08 0.04 .062 G 20.11 0.08 .174 0.11 0.03 .001 111
Vocabulary TPH2 rs1352250 A 0.19 0.08 .017 G 20.05 0.04 .242 G 20.02 0.08 .802 0.07 0.03 .036 111
Vocabulary GABRB3 rs2114217 T 20.21 0.10 .030 A 0.08 0.06 .196 A 0.19 0.12 .103 0.13 0.05 .008 111
Vocabulary CRHR1 rs12938031 G 20.23 0.08 .006 G 20.04 0.04 .337 G 20.03 0.08 .695 0.07 0.03 .032 111
Abbreviations: RANN, Reference Ability Neural Network; ROSMAP, Religious Orders Study and RushMemory and Aging Project; SE, standard error; SNP,
single-nucleotide polymorphism.
Only SNPs reaching nominal significance (P .05) are shown (ROSMAP_b1 and ROSMAP_b2 correspond to the two independent genotype batches for the
cohort). Strongest SNP associations within each of the reference abilities are highlighted in bold.
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TheDRD4 gene is widely heavily expressed in the frontal
cortex [61], where it appears to modulate GABAergic
signaling [62], suggesting a potential mechanism underlying
the involvement of D4 receptors in frontal cortex cognitive
function.
However, the relationship between dopamine and cogni-
tive performance is highly complex and the precise role of
DA in cognition is not well understood. Pharmacologic
studies have shown that in disorders such as schizophrenia,
cognitive symptoms can be improved by specifically admin-
istrating blockers of dopamine D4 receptors [63]. Further-
more, the cognitive benefits derived from DRD4 blocking
seem to be only effective when other dopamine receptors
are not blocked, suggesting a unique role forDRD4 in inhib-
iting cognitive processes [64]. Current research suggests that
manipulation of dopamine will have paradoxical cognitive
consequences depending on the type of task under study,
the brain region that is implicated, and the baseline levels
of dopamine in that brain region [65].
Variants in DRD4 gene have associated with schizo-
phrenia [66] and bipolar disorder [67]. A 48 bp short tandem
repeat polymorphism in the exon 3 is the most replicated ge-
netic risk factor for attention-deficit/hyperactivity disorder
(ADHD) [68]. In a sample of 245 healthy Caucasians adults,
the same polymorphism appeared to be strongly associated
with slower speed of performance on multiple cognitive
tasks [69].
The DRD4 promoter variant rs3758653 reported here has
been previously associated with schizophrenia [66], heroin
addiction [66], and AD [70]. To our knowledge, this is the
first report implicating the same DRD4 polymorphism in
cognitively European healthy individuals with a sample
size.1000. In a smaller sample (n5w500 healthy Chinese
adults), a correlation between this SNP and the speed of pro-
cessing of the Tower of Hanoi task was reported [71].
Regarding the functional implications of the gene’s pro-
moter variants, it has been shown that theDRD4 gene’s poly-
morphisms lead to the difference in how well the receptors
bind with dopamine and similar compounds [72], and there-
fore it has been assumed this basic difference leads to the dif-
ferences observed in the phenotypes.
One unique feature of this study was the four selected
cognitive domains capturing most variance in age-related
cognitive function. Researchers often evaluate neural corre-
lates of age-related cognitive changes using the performance
of one specific task that purportedly taps a domain. In
contrast, it has been repeatedly demonstrated that perfor-
mance across the age span on large batteries of diverse
cognitive tests can be parsimoniously represented by a set
of four RAs: episodic memory, fluid ability, perceptual
speed, and vocabulary [73,74]. On the basis of these
findings, Salthouse and Ferrer-Caja [37] have argued that a
productive and efficient approach to cognitive aging
research is to try to understand how aging impacts perfor-
mance of this small set of general RAs, rather than on spe-
cific tasks. Thus, we used three measures per domain that
we found to be compatible with Salthouse’ s latent variable
measures of the four RAs [38]. We could therefore be confi-
dent that we were using comprehensive and accurate mea-
sures of cognitive aging.
There are some limitations of our study. First, the limited
sample size of the discovery cohort may reduce statistical
power to detect a true effect [75]. However, the fact that we
replicated our finding in an independent cohort provides further
support for the association. Second, it is possible that the list of
target genes studied failed to include the genes thatmay play an
important role in cognitive function. Third, we cannot discard
thepossibility that environmental factorsmayexplain thediffer-
ences observed in cognitive performance, in fact, due to the
complex nature of cognition, is highly likely that there may
be an interaction between genetic and environmental factors.
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RESEARCH IN CONTEXT
1. Systematic review: Genetic variants strongly influ-
ence cognition in both pathologic and normal varia-
tions. Candidate gene and genome-wide association
study have reported potential loci, but no specific
genes have been identified. We investigated whether
genetic variants in genes in different neurologic
molecular networks are associated with domains
capturing variance in age-related cognition.
2. Interpretation: Our results identified a variant in the
promoter region of the dopamine receptor D4 gene
strongly associated with performance on speed of
processing. To our knowledge, this is the first report
implicating this gene in a large cohort (n5 1021) of
cognitively healthy European subjects. The identifi-
cation of genetic variants influencing healthy cogni-
tion is crucial to understand the natural disease
resistance to brain neurodegeneration.
3. Future directions: The precise role of dopamine in
cognition is still not well understood. Future studies
will require whole genome gene sequencing in larger
samples followed by functional genomic studies
aimed to identify the causal variants.
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